A5087346045- Head and Neck Cancer Studies
- Breast Cancer Treatment Studies
- Cancer Diagnosis and Treatment
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Advanced Radiotherapy Techniques
- Dysphagia Assessment and Management
- Colorectal and Anal Carcinomas
- Head and Neck Surgical Oncology
- Salivary Gland Tumors Diagnosis and Treatment
- BRCA gene mutations in cancer
- Advances in Oncology and Radiotherapy
- Economic and Financial Impacts of Cancer
- Pituitary Gland Disorders and Treatments
- Advanced Breast Cancer Therapies
- Cancer survivorship and care
- Radiomics and Machine Learning in Medical Imaging
- HER2/EGFR in Cancer Research
- Nutrition and Health in Aging
- COVID-19 and healthcare impacts
- Multiple and Secondary Primary Cancers
- Healthcare Systems and Challenges
- Cancer Treatment and Pharmacology
- Oral health in cancer treatment
- Thyroid Cancer Diagnosis and Treatment
Royal Shrewsbury Hospital
2015-2024
Shrewsbury and Telford Hospital NHS Trust
2016-2022
Scottish Association of the Teachers of History
2020
New Cross Hospital
2014
The Royal Wolverhampton NHS Trust
2014
Wolverhampton Hospital
2013
Edwards Lifesciences (Switzerland)
2013
University of Wolverhampton
2013
Edwards (United Kingdom)
2011-2012
Queen Elizabeth Hospital Birmingham
2011-2012
BackgroundThe incidence of human papillomavirus (HPV)-positive oropharyngeal cancer, a disease affecting younger patients, is rapidly increasing. Cetuximab, an epidermal growth factor receptor inhibitor, has been proposed for treatment de-escalation in this setting to reduce the toxicity standard cisplatin treatment, but no randomised evidence exists efficacy strategy.MethodsWe did open-label controlled phase 3 trial at 32 head and neck centres Ireland, Netherlands, UK, patients aged 18...
BackgroundAdjuvant trastuzumab significantly improves outcomes for patients with HER2-positive early breast cancer. The standard treatment duration is 12 months but shorter could provide similar efficacy while reducing toxicities and cost. We aimed to investigate whether 6-month adjuvant non-inferior the 12-month regarding disease-free survival.MethodsThis study an open-label, randomised phase 3 non-inferiority trial. Patients were recruited from 152 centres in UK. randomly assigned cancer,...
<h2>Summary</h2><h3>Background</h3> Most newly diagnosed oropharyngeal and hypopharyngeal cancers are treated with chemoradiotherapy curative intent but at the consequence of adverse effects on quality life. We aimed to investigate if dysphagia-optimised intensity-modulated radiotherapy (DO-IMRT) reduced radiation dose dysphagia aspiration related structures improved swallowing function compared standard IMRT. <h3>Methods</h3> DARS was a parallel-group, phase 3, multicentre, randomised,...
<h3>Importance</h3> Patients with breast cancer remain at risk of relapse after adjuvant therapy. Celecoxib has shown antitumor effects in preclinical models human cancer, but clinical evidence is lacking. <h3>Objective</h3> To evaluate the role celecoxib as an addition to conventional therapy for women ERBB2 (formerly HER2)–negative primary cancer. <h3>Design, Setting, and Participants</h3> The Randomized European Trial (REACT) was a phase 3, randomized, double-blind study conducted 160...
6508 Background: Most newly diagnosed oro- & hypopharngeal cancers (OPC, HPC) are treated with (chemo)RT curative intent but at the consequence of adverse effects on quality life. CRUK/14/014 investigated if using Do-IMRT to reduce RT dose dysphagia/aspiration related structures (DARS) improved swallowing function compared S-IMRT. Methods: Patients T1-4, N0-3, M0 OPC/HPC were randomised 1:1 S-IMRT (65 Gray (Gy)/30 fractions (f) primary nodal tumour; 54Gy/30f remaining pharyngeal subsite...
Abstract Background For a tumour profiling test to be of value, it needs demonstrate that is changing clinical decisions, improving confidence, and economic benefit. This trial evaluated the use Oncotype DX Breast Recurrence Score® assay against these criteria in 680 women with hormone receptor-positive (HR+), HER2-negative early breast cancer 1–3 lymph nodes positive (LN+) UK National Health Service (NHS). Methods Prior receipt Score (RS) result, both physician patient were asked state...
The complexity of radiotherapy planning is increasing rapidly. Delivery and subject to detailed quality assurance (QA) checks. weakest link often the oncologists' delineation clinical target volume (CTV). Weekly departmental meetings for QA (RTQA) were introduced into Royal Wolverhampton Hospital, Wolverhampton, UK, in October 2011. This article describes impact this on patient care.CTVs megavoltage photon courses all radical, adjuvant palliative treatments longer than five fractions (with...
The UK radiotherapy (RT) workforce needs novel strategies to manage increasing demand. appointment of a palliative RT (PRT) consultant radiographer (CR) offers potential solution enhance patient pathways providing timely RT. This article examined the impact one such appointment.Two prospective audits were completed 1 year apart. All patients receiving PRT for bone metastases between 01/01/2014-31/03/2014 (Audit 1) and 01/01/2015-31/01/2015 2) included. Data collected included demographics,...
Abstract Introduction Oral mucositis is common for patients undergoing chemoradiotherapy squamous cell carcinoma of the head and neck (SCCHN). Despite significant detrimental sequelae associated, there no consensus on optimum mouth care regimen. This prospective audit aims to record dysphagia toxicity level analgesia prescribed when recent products: MuGard™, Caphosol ® Episil are compared with our standard departmental Methods Patients concurrent locally advanced SCCHN at University Hospital...
Two postmenopausal women with breast cancer developed acute confusion and seizures, less than 24 hours after the first cycle of neoadjuvant chemotherapy fluorouracil, epirubicin low-dose cyclophosphamide. They were found to have severe, life-threatening hyponatraemia sodium levels 113 115 mEq/L, respectively. Both made a full recovery within admission slow correction levels. Following investigational workup, most likely diagnosis was cyclophosphamide-associated syndrome inappropriate...
Parameters have been derived in head and neck cancer to account for the additional biological effective dose provided by synchronous chemotherapy. The purpose of this study was establish whether such parameters could be used predict local control differences anal cancer.In two randomised trials radiotherapy vs chemoradiotherapy randomising between different chemotherapy regimens were identified. To arms first studies, a global value 9.3 Gy biologically employed. For last trials, values...
The onset of the COVID-19 pandemic necessitated rapid changes to practice head and neck oncology in UK. There was a delay between release guidelines from cancer societies networks, leading variable response individual centres. This survey conducted assess pre-Covid-19 standard for patients treatment modifications introduced during first wave
Objective: Attempts have been made to model the contribution of concomitant chemotherapy radiotherapy in terms biological effective dose (BED) for major squamous cell carcinoma (SCC) sub-sites. Despite SCC’s sharing common aetiology, different chemoradiotherapy regimens are used clinical practice. This study aims compare BED across SCC sub-sites using two radiobiological models; intuitive and Poisson methods its calculation. Methods: Phase 3 trials versus conventional fractionation head...
Abstract Introduction: The addition of adjuvant chemotherapy to hormonal therapy is recommended for patients with lymph node-positive (LN+ve), estrogen receptor positive (ER+), HER2-ve early breast cancer, despite the fact that many women will remain disease-free even if they do not receive chemotherapy. Therefore, a number LN+ EBC may be unnecessarily exposed toxicities no treatment benefit. In UK, Oncotype DX® Recurrence Score (RS) by NICE routine testing in ER+ HER2-ve, node negative...
Abstract Introduction: For a test to be of value, it needs demonstrate that is changing clinical decisions, improving confidence and economic benefit. This trial looked at the use Oncotype DX Breast Recurrence Score ® (RS) assay against these criteria in 680 women with hormone receptor positive (HR+), HER2 negative early breast cancer 1 3 lymph nodes (LN+) UK National Health Service (NHS) (5 teaching 9 district general hospitals) between 2017 2022. Methods: Patients LN+ who were willing fit...